• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经睫状体平坦部玻璃体切割术、氟轻松醋酸酯植入和硅油注入治疗慢性、难治性葡萄膜炎性低眼压。

Pars plana vitrectomy, fluocinolone acetonide implantation, and silicone oil infusion for the treatment of chronic, refractory uveitic hypotony.

机构信息

Department of Ophthalmology, Duke University Eye Center, Durham, North Carolina 27710, USA.

出版信息

Am J Ophthalmol. 2011 Nov;152(5):849-56.e1. doi: 10.1016/j.ajo.2011.04.035. Epub 2011 Jul 26.

DOI:10.1016/j.ajo.2011.04.035
PMID:21794844
Abstract

PURPOSE

To assess the feasibility and outcomes of combining fluocinolone acetonide sustained drug delivery implant insertion, pars plana vitrectomy, and silicone oil infusion to treat patients with chronic, refractory ocular hypotony resulting from uveitis.

DESIGN

Retrospective chart review.

METHODS

A retrospective, institutional chart review was performed. Outcome measures included visual acuity, intraocular pressure, and adverse events.

RESULTS

A total of 13 eyes of 11 patients were studied. All patients were women, had a mean age of 57 years (range, 26 to 73 years), and had a diagnosis of panuveitis. The mean duration of preoperative hypotony was 42 months (range, 11 to 108 months). Patients were followed up on average for 22 months (range, 9 to 46 months) after the combined surgical procedure. The mean preoperative visual acuity was 20/1000 (logarithm of the minimal angle of resolution, 1.7). At the 6- and 12-month visits, the mean visual acuity remained stable at 20/800 (logarithm of the minimal angle of resolution, 1.6; P = .74) and 20/600 (P = .34), respectively. At baseline, the mean intraocular pressure (IOP) was 2.3 mm Hg. The average IOP was 5.9 mm Hg, 5.1 mm Hg, and 5.0 mm Hg at 6, 12, and 24 months after surgery, respectively. The increase in IOP relative to the baseline IOP was statistically significant at 6 and 12 months (P = .027 and P = .004, respectively). The duration of preoperative hypotony inversely correlated with the IOP at 6 months (P = .027). No intraoperative complications were encountered and the procedure was well tolerated.

CONCLUSIONS

Fluocinolone acetonide implantation combined with pars plana vitrectomy and silicone oil infusion is feasible and is well tolerated in the management of chronic, refractory ocular hypotony associated with uveitis.

摘要

目的

评估氟轻松醋酸酯持续药物输送植入物插入、玻璃体切除术和平房硅油填充联合治疗葡萄膜炎引起的慢性、难治性低眼压的可行性和结果。

设计

回顾性图表审查。

方法

进行了回顾性的机构图表审查。观察指标包括视力、眼压和不良事件。

结果

共研究了 11 名患者的 13 只眼。所有患者均为女性,平均年龄 57 岁(范围 26 至 73 岁),诊断为全葡萄膜炎。术前低眼压的平均持续时间为 42 个月(范围 11 至 108 个月)。患者在联合手术后平均随访 22 个月(范围 9 至 46 个月)。术前平均视力为 20/1000(最小分辨角对数,1.7)。在 6 个月和 12 个月的随访中,平均视力分别稳定在 20/800(最小分辨角对数,1.6;P=0.74)和 20/600(P=0.34)。基线时,平均眼压(IOP)为 2.3mmHg。术后 6、12 和 24 个月时的平均 IOP 分别为 5.9mmHg、5.1mmHg 和 5.0mmHg。与基线 IOP 相比,IOP 的升高在 6 个月和 12 个月时具有统计学意义(P=0.027 和 P=0.004)。术前低眼压的持续时间与 6 个月时的眼压呈负相关(P=0.027)。术中未发生并发症,患者耐受性良好。

结论

氟轻松醋酸酯植入物联合玻璃体切除术和平房硅油填充治疗与葡萄膜炎相关的慢性、难治性低眼压是可行的,且患者耐受性良好。

相似文献

1
Pars plana vitrectomy, fluocinolone acetonide implantation, and silicone oil infusion for the treatment of chronic, refractory uveitic hypotony.经睫状体平坦部玻璃体切割术、氟轻松醋酸酯植入和硅油注入治疗慢性、难治性葡萄膜炎性低眼压。
Am J Ophthalmol. 2011 Nov;152(5):849-56.e1. doi: 10.1016/j.ajo.2011.04.035. Epub 2011 Jul 26.
2
Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.联合氟轻松醋酸酯玻璃体腔内植入和青光眼引流装置植入治疗慢性葡萄膜炎和青光眼。
Am J Ophthalmol. 2010 May;149(5):800-6.e1. doi: 10.1016/j.ajo.2009.12.009. Epub 2010 Feb 26.
3
Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.联合氟轻松丙酮奈德眼内给药系统植入、超声乳化术及人工晶状体植入治疗严重葡萄膜炎。
Am J Ophthalmol. 2008 Oct;146(4):589-594. doi: 10.1016/j.ajo.2008.05.035. Epub 2008 Jul 17.
4
Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.醋酸氟轻松植入剂治疗后葡萄膜炎的一项试点试验的长期随访结果
Ophthalmology. 2005 Jul;112(7):1192-8. doi: 10.1016/j.ophtha.2005.03.013.
5
Boston type 1 keratoprosthesis combined with silicone oil for treatment of hypotony in prephthisical eyes.波士顿Ⅰ型角膜镜联合硅油治疗前期眼球低眼压。
Cornea. 2011 Oct;30(10):1105-9. doi: 10.1097/ICO.0b013e318207f3bb.
6
Treating uveitis-associated hypotony with pars plana vitrectomy and silicone oil injection.采用经平坦部玻璃体切除术联合硅油注气治疗葡萄膜炎相关性低眼压。
Retina. 2010 Jan;30(1):140-5. doi: 10.1097/IAE.0b013e3181b32f06.
7
Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis.氟轻松丙酮缩醇缓释植入剂用于慢性葡萄膜炎的再植入
Am J Ophthalmol. 2008 Apr;145(4):667-675. doi: 10.1016/j.ajo.2007.11.008. Epub 2008 Jan 28.
8
Successful outcome of pars plana vitreous surgery in chronic hypotony due to uveitis.葡萄膜炎所致慢性低眼压情况下经睫状体平坦部玻璃体手术的成功结果。
Retina. 2009 May;29(5):638-43. doi: 10.1097/IAE.0b013e31819a5fd8.
9
Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.氟轻松醋酸酯眼内植入剂治疗非感染性葡萄膜炎患者的眼内压结果。
Ophthalmology. 2011 Oct;118(10):1927-31. doi: 10.1016/j.ophtha.2011.02.042. Epub 2011 Jun 8.
10
Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.用于慢性视网膜中央静脉阻塞的曲安奈德缓释给药装置:12个月结果
Am J Ophthalmol. 2008 Aug;146(2):285-291. doi: 10.1016/j.ajo.2008.03.025. Epub 2008 Jun 4.

引用本文的文献

1
Chronic hypotony management using endoscopy-assisted vitrectomy after severe ocular trauma or vitrectomy.严重眼外伤或玻璃体切除术后采用内镜辅助玻璃体切除术治疗慢性低眼压
Int J Ophthalmol. 2023 Jun 18;16(6):947-954. doi: 10.18240/ijo.2023.06.18. eCollection 2023.
2
Intra-vitreal gas injection and supine positioning for hypotony post-intrascleral intraocular lens fixation.玻璃体内气体注射及仰卧位用于巩膜内人工晶状体固定术后低眼压
Am J Ophthalmol Case Rep. 2022 Feb 12;26:101385. doi: 10.1016/j.ajoc.2022.101385. eCollection 2022 Jun.